Substituted indole-2-carboxylates as in vivo potent antagonists acting as the strychnine-insensitive glycine binding site. 1997

R Di Fabio, and A M Capelli, and N Conti, and A Cugola, and D Donati, and A Feriani, and P Gastaldi, and G Gaviraghi, and C T Hewkin, and F Micheli, and A Missio, and M Mugnaini, and A Pecunioso, and A M Quaglia, and E Ratti, and L Rossi, and G Tedesco, and D G Trist, and A Reggiani
Glaxo Wellcome S.p.A., Medicines Research Centre, Verona, Italy. rdf26781@ggr.co.uk

A series of indole-2-carboxylates bearing suitable chains at the C-3 position of the indole nucleus was synthesized and evaluated in terms of in vitro affinity using [3H]glycine binding assay and in vivo potency by inhibition of convulsions induced by N-methyl-D-aspartate (NMDA) in mice. 3-[2-[(Phenylamino)carbonyl]ethenyl]-4,6-dichloroindole-2-carboxyl ic acid (8) was an antagonist at the strychnine-insensitive glycine binding site (noncompetitive inhibition of the binding of [3H]TCP, pA2 = 8.1) displaying nanomolar affinity for the glycine binding site (pKi = 8.5), coupled with high glutamate receptor selectivity (> 1000-fold relative to the affinity at the NMDA, AMPA, and kainate binding sites). This indole derivative inhibited convulsions induced by NMDA in mice, when administered by both iv and po routes (ED50 = 0.06 and 6 mg/kg, respectively). The effect of the substituents on the terminal phenyl ring of the C-3 side chain was investigated. QSAR analysis suggested that the pKi value decreases with lipophilicity and steric bulk of substituents and increases with the electron donor resonance effect of the groups present in the para position of the terminal phenyl ring. According to these results the terminal phenyl ring of the C-3 side chain should lie in a nonhydrophobic pocket of limited size, refining the proposed pharmacophore model of the glycine binding site associated with the NMDA receptor.

UI MeSH Term Description Entries
D007211 Indoles Benzopyrroles with the nitrogen at the number one carbon adjacent to the benzyl portion, in contrast to ISOINDOLES which have the nitrogen away from the six-membered ring.
D009682 Magnetic Resonance Spectroscopy Spectroscopic method of measuring the magnetic moment of elementary particles such as atomic nuclei, protons or electrons. It is employed in clinical applications such as NMR Tomography (MAGNETIC RESONANCE IMAGING). In Vivo NMR Spectroscopy,MR Spectroscopy,Magnetic Resonance,NMR Spectroscopy,NMR Spectroscopy, In Vivo,Nuclear Magnetic Resonance,Spectroscopy, Magnetic Resonance,Spectroscopy, NMR,Spectroscopy, Nuclear Magnetic Resonance,Magnetic Resonance Spectroscopies,Magnetic Resonance, Nuclear,NMR Spectroscopies,Resonance Spectroscopy, Magnetic,Resonance, Magnetic,Resonance, Nuclear Magnetic,Spectroscopies, NMR,Spectroscopy, MR
D002264 Carboxylic Acids Organic compounds containing the carboxy group (-COOH). This group of compounds includes amino acids and fatty acids. Carboxylic acids can be saturated, unsaturated, or aromatic. Carboxylic Acid,Acid, Carboxylic,Acids, Carboxylic
D002540 Cerebral Cortex The thin layer of GRAY MATTER on the surface of the CEREBRAL HEMISPHERES that develops from the TELENCEPHALON and folds into gyri and sulci. It reaches its highest development in humans and is responsible for intellectual faculties and higher mental functions. Allocortex,Archipallium,Cortex Cerebri,Cortical Plate,Paleocortex,Periallocortex,Allocortices,Archipalliums,Cerebral Cortices,Cortex Cerebrus,Cortex, Cerebral,Cortical Plates,Paleocortices,Periallocortices,Plate, Cortical
D005998 Glycine A non-essential amino acid. It is found primarily in gelatin and silk fibroin and used therapeutically as a nutrient. It is also a fast inhibitory neurotransmitter. Aminoacetic Acid,Glycine, Monopotassium Salt,Glycine Carbonate (1:1), Monosodium Salt,Glycine Carbonate (2:1), Monolithium Salt,Glycine Carbonate (2:1), Monopotassium Salt,Glycine Carbonate (2:1), Monosodium Salt,Glycine Hydrochloride,Glycine Hydrochloride (2:1),Glycine Phosphate,Glycine Phosphate (1:1),Glycine Sulfate (3:1),Glycine, Calcium Salt,Glycine, Calcium Salt (2:1),Glycine, Cobalt Salt,Glycine, Copper Salt,Glycine, Monoammonium Salt,Glycine, Monosodium Salt,Glycine, Sodium Hydrogen Carbonate,Acid, Aminoacetic,Calcium Salt Glycine,Cobalt Salt Glycine,Copper Salt Glycine,Hydrochloride, Glycine,Monoammonium Salt Glycine,Monopotassium Salt Glycine,Monosodium Salt Glycine,Phosphate, Glycine,Salt Glycine, Monoammonium,Salt Glycine, Monopotassium,Salt Glycine, Monosodium
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D001665 Binding Sites The parts of a macromolecule that directly participate in its specific combination with another molecule. Combining Site,Binding Site,Combining Sites,Site, Binding,Site, Combining,Sites, Binding,Sites, Combining
D001667 Binding, Competitive The interaction of two or more substrates or ligands with the same binding site. The displacement of one by the other is used in quantitative and selective affinity measurements. Competitive Binding
D013329 Structure-Activity Relationship The relationship between the chemical structure of a compound and its biological or pharmacological activity. Compounds are often classed together because they have structural characteristics in common including shape, size, stereochemical arrangement, and distribution of functional groups. Relationship, Structure-Activity,Relationships, Structure-Activity,Structure Activity Relationship,Structure-Activity Relationships
D013331 Strychnine An alkaloid found in the seeds of STRYCHNOS NUX-VOMICA. It is a competitive antagonist at glycine receptors and thus a convulsant. It has been used as an analeptic, in the treatment of nonketotic hyperglycinemia and sleep apnea, and as a rat poison. Strychnine Nitrate,Nitrate, Strychnine

Related Publications

R Di Fabio, and A M Capelli, and N Conti, and A Cugola, and D Donati, and A Feriani, and P Gastaldi, and G Gaviraghi, and C T Hewkin, and F Micheli, and A Missio, and M Mugnaini, and A Pecunioso, and A M Quaglia, and E Ratti, and L Rossi, and G Tedesco, and D G Trist, and A Reggiani
August 1999, Archiv der Pharmazie,
R Di Fabio, and A M Capelli, and N Conti, and A Cugola, and D Donati, and A Feriani, and P Gastaldi, and G Gaviraghi, and C T Hewkin, and F Micheli, and A Missio, and M Mugnaini, and A Pecunioso, and A M Quaglia, and E Ratti, and L Rossi, and G Tedesco, and D G Trist, and A Reggiani
September 1992, The Journal of pharmacology and experimental therapeutics,
R Di Fabio, and A M Capelli, and N Conti, and A Cugola, and D Donati, and A Feriani, and P Gastaldi, and G Gaviraghi, and C T Hewkin, and F Micheli, and A Missio, and M Mugnaini, and A Pecunioso, and A M Quaglia, and E Ratti, and L Rossi, and G Tedesco, and D G Trist, and A Reggiani
April 1991, Journal of medicinal chemistry,
R Di Fabio, and A M Capelli, and N Conti, and A Cugola, and D Donati, and A Feriani, and P Gastaldi, and G Gaviraghi, and C T Hewkin, and F Micheli, and A Missio, and M Mugnaini, and A Pecunioso, and A M Quaglia, and E Ratti, and L Rossi, and G Tedesco, and D G Trist, and A Reggiani
October 2001, Farmaco (Societa chimica italiana : 1989),
R Di Fabio, and A M Capelli, and N Conti, and A Cugola, and D Donati, and A Feriani, and P Gastaldi, and G Gaviraghi, and C T Hewkin, and F Micheli, and A Missio, and M Mugnaini, and A Pecunioso, and A M Quaglia, and E Ratti, and L Rossi, and G Tedesco, and D G Trist, and A Reggiani
August 1997, Pharmacology, biochemistry, and behavior,
R Di Fabio, and A M Capelli, and N Conti, and A Cugola, and D Donati, and A Feriani, and P Gastaldi, and G Gaviraghi, and C T Hewkin, and F Micheli, and A Missio, and M Mugnaini, and A Pecunioso, and A M Quaglia, and E Ratti, and L Rossi, and G Tedesco, and D G Trist, and A Reggiani
March 1995, European journal of pharmacology,
R Di Fabio, and A M Capelli, and N Conti, and A Cugola, and D Donati, and A Feriani, and P Gastaldi, and G Gaviraghi, and C T Hewkin, and F Micheli, and A Missio, and M Mugnaini, and A Pecunioso, and A M Quaglia, and E Ratti, and L Rossi, and G Tedesco, and D G Trist, and A Reggiani
September 1999, Journal of medicinal chemistry,
R Di Fabio, and A M Capelli, and N Conti, and A Cugola, and D Donati, and A Feriani, and P Gastaldi, and G Gaviraghi, and C T Hewkin, and F Micheli, and A Missio, and M Mugnaini, and A Pecunioso, and A M Quaglia, and E Ratti, and L Rossi, and G Tedesco, and D G Trist, and A Reggiani
February 1994, Journal of medicinal chemistry,
R Di Fabio, and A M Capelli, and N Conti, and A Cugola, and D Donati, and A Feriani, and P Gastaldi, and G Gaviraghi, and C T Hewkin, and F Micheli, and A Missio, and M Mugnaini, and A Pecunioso, and A M Quaglia, and E Ratti, and L Rossi, and G Tedesco, and D G Trist, and A Reggiani
September 1992, Journal of medicinal chemistry,
R Di Fabio, and A M Capelli, and N Conti, and A Cugola, and D Donati, and A Feriani, and P Gastaldi, and G Gaviraghi, and C T Hewkin, and F Micheli, and A Missio, and M Mugnaini, and A Pecunioso, and A M Quaglia, and E Ratti, and L Rossi, and G Tedesco, and D G Trist, and A Reggiani
July 1992, Epilepsy research,
Copied contents to your clipboard!